| Description | Enoblituzumab is a humanized IgG1 κmab monoclonal antibody that recognizes human B7-H3 protein and can be used to study solid tumors such as non-small cell lung cancer (NSCLC). |
| In vitro | 与B7-H3相互作用时，enoblituzumab能强烈引发针对广泛癌症细胞的抗体依赖性细胞毒性(ADCC)[2]。在0.01 ng/mL至10 mg/mL浓度范围内，enoblituzumab借由猕猴外周血单核细胞(PBMCs)介导针对A498细胞的抗体依赖性细胞毒性(ADCC)[3]。 |
| In vivo | 在小鼠(mCD16-/-hCD16A+)中，通过基因编辑技术敲除了小鼠的CD16基因，并转基因人类CD16A-158F的情况下，enoblituzumab（5 mg/kg；静脉注射；单剂量）的半衰期约为249小时，最大浓度Cmax达到43 mg/mL[3]。此外，enoblituzumab（0.1-10 mg/kg；静脉注射；每周一次；共5周）在表达B7-H3的肾细胞和膀胱癌异种移植小鼠模型中，展现出了强大的抗肿瘤活性[3]。 |
| Synonyms | MGA271, TJ-271 |
| molecular weight | N/A |
| CAS | 1353485-38-7 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Hińcza-Nowak K, et al. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy. Genes (Basel). 2021 Sep 28;12(10):1534. 2. Chapoval, et al. Immune Checkpoints of the B7 Family. Part Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors. Russ J Bioorg Chem 45, 321–334 (2019). 3. Loo D, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3834-45. |